A3B, for example, could provide a mutation rate that is in some cases beneficial favouring immune responses following immunotherapy with a positive outcome for the cancer patients [133], but in other cases, it is related with poor clinical outcomes [34,140,141]. Here, APOBEC3B is linked to cancer.